Core Viewpoint - Viatris Bio (01873.HK) has reported a significant turnaround in its financial performance for 2024, leading to a strong increase in stock price, with a year-to-date gain of 97.67% [1][2]. Financial Performance - The company expects to achieve profitability in 2024, projecting a net profit between 210 million RMB and 240 million RMB, with shareholder net profit ranging from 150 million RMB to 180 million RMB [3]. - In contrast, the company reported a net loss of 99.8 million RMB and a shareholder net loss of 116.1 million RMB for 2023 [4]. Business Growth Drivers - The growth is attributed to the recovery of the CRO business in the second half of the year, improved operational efficiency, and investment income from milestone payments [5]. - Viatris Bio operates as an investment holding company, providing structure-based drug discovery services to global biotech and pharmaceutical clients, primarily in the US, China, Europe, and other regions [5]. Technological Advancements - The company showcased advanced technology platforms at the BPI WEEK 2025, particularly in antibody drug development and XDC conjugate drug research, which garnered significant attention [5]. - Viatris Bio offers a comprehensive service in antibody drug development, from target antigen preparation to candidate functional antibody construction and expression [5][6]. AI Integration - The company has made significant strides in AI, deploying the DeepSeek-R1 model to enhance intelligent workflows [9]. - Viatris Bio has established an AIDD/CADD platform for drug development, which has evolved into a full-cycle AI-enabled system, accelerating the drug development process [10][12]. Strategic Partnerships and Market Position - The company has successfully cleared its convertible bond repayment pressure after attracting strategic investors like Temasek and Honghui in 2023, positioning itself for a strong 2024 [12]. - According to research from China Merchants Securities, the company's CRO business is well-positioned to benefit from industry recovery, with a steady restoration of CRO orders and ongoing progress in the Langhua Pharmaceutical service project [13].
维亚生物预计2024年扭亏为盈 今年股价接近翻番